LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $74.1111.

A number of analysts recently commented on the company. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday. Mizuho boosted their price target on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. KeyCorp assumed coverage on shares of LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective on the stock. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Barclays increased their price target on shares of LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a research report on Friday, January 9th.

LivaNova News Summary

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 results beat on both revenue and adjusted EPS; revenue was ~$360.9M (up ~12% y/y) and adjusted EPS topped consensus — management issued FY‑2026 adjusted EPS guidance of $4.15–$4.25, above Street estimates, which is the main near-term catalyst. Read More.
• Positive Sentiment: Analyst upgrade/price-target lift: Needham raised its price target to $81 and reiterated a Buy rating, reinforcing bullish sentiment following the results and guidance. Read More.
• Positive Sentiment: Short interest declined materially in February (down ~16.6% to ~2.03M shares), lowering potential downward pressure from short squeezes and signaling reduced bearish positioning into the earnings update.
• Neutral Sentiment: Management materials and the full earnings call transcript are available for deeper read-throughs (useful for assessing margin drivers and product/service momentum). Read More. · Read More.
• Neutral Sentiment: Market commentary is starting to assess longer-term drivers such as reimbursement gains and a new data partnership (Orrum) that could reshape cardiac-care positioning; these are potential catalysts but currently speculative. Read More. · Read More.
• Negative Sentiment: GAAP metrics and margins still show weaknesses: reported GAAP diluted EPS was lower than adjusted EPS and the company reported a negative net margin (~‑16%), suggesting non‑operating items or charges and that underlying profitability still needs improvement. Investors should monitor whether adjusted guidance is supported by sustained operating margin improvement. Read More.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Allianz Asset Management GmbH purchased a new stake in shares of LivaNova during the 3rd quarter worth approximately $7,687,000. LSV Asset Management increased its position in LivaNova by 25.4% in the third quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after purchasing an additional 136,600 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in LivaNova by 8.1% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock valued at $18,315,000 after purchasing an additional 26,202 shares in the last quarter. New York State Common Retirement Fund lifted its position in LivaNova by 79.6% during the second quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after purchasing an additional 38,451 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in LivaNova during the second quarter valued at $1,378,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Performance

Shares of LIVN stock opened at $70.29 on Thursday. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average price of $64.41 and a 200-day moving average price of $58.81. LivaNova has a 52 week low of $32.48 and a 52 week high of $70.78. The firm has a market capitalization of $3.84 billion, a PE ratio of -17.57 and a beta of 0.97.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The company had revenue of $360.86 million for the quarter, compared to analysts’ expectations of $354.31 million. During the same quarter last year, the company posted $0.81 earnings per share. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities research analysts expect that LivaNova will post 2.85 earnings per share for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.